TCL Archive A Message From NCI: “We Deeply Regret The Need To Eliminate This Program.” AP4 Applicants And Corporate Partners Spent Years, Money, Before NCI Pulled The Plug On Novel Public-Private Partnerships. Von Eschenbach Called AP4 “A New Paradigm” For Drug Development. NCI Executive Committee “Prioritized” Programs. April 21, 2006
TCL Archive FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March. January 21, 2005
TCL Archive Tarceva-Induced Rash Strongly Associated With Longer Survival, Sponsor Finds July 27, 2007
TCL Archive In Brief: Korsmeyer Wins Bristol-Meyers Squibb Award; Lichter Names President-Elect of ASCO April 18, 1997
TCL Archive In Brief: NCI Tells Cooperative Groups To Submit applications For Extra Multimodality Funds November 28, 1975
